PENEDERM NDA FILINGS FOR RETINOIC ACID GEL AND CREAM FOR ACNE
PENEDERM NDA FILINGS FOR RETINOIC ACID GEL AND CREAM FOR ACNE are pending at FDA, the company indicates in a May 2 "red herring" prospectus for 1.7 mil. shares of common stock being sold by Penederm shareholders. Foster City, Calif.-based Penederm said that Phase III trials that enrolled about 400 subjects were completed in the summer of 1993, and both NDAs were originally submitted in September. Resubmissions were made in March with additional data after initial discussions with FDA.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth